SNCA and Parkinson disease: Evidence have shown that α-synuclein could be released from neurons into body fluids, including CSF and plasma, contributing to cell-to-cell transmission of α-synuclein pathology in the disease process [1] and leading to numerous studies exploring plasma α-synuclein as a potential disease biomarker in patients with PD.